Trial · NCT06095596
Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
NCT06095596, Not applicable, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis. Trials, record NCT06095596. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06095596
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
- NCT number
- NCT06095596
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 334 participants, estimated
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Upadacitinib, Vedolizumab
- First posted
- 2023-10-23
- Last updated
- 2026-04-28
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 8th-week endoscopic remission rate | 8th-week | endoscopic subscale (ESS) =0, which defined as endoscopic remission |
| Secondary | Clinical remission rate at the 8th week | 8th-week | Clinical remission is defined as a total Mayo score ≤2, with no individual subscore \>1 and a rectal bleeding subscore of 0. |
| Secondary | clincial response rate at 8th-week | 8th-week | Clinical response is defined as a decrease in total Mayo score by ≥3 points and ≥30% from baseline, with a decrease in rectal bleeding subscore by ≥1 point or an absolute rectal bleeding subscore of 0 or 1. |
| Secondary | Endoscopic response rate at 8th-week | 8th-week | Endoscopic response is defined as a decrease in the Mayo endoscopic subscore by ≥1 point from baseline |
| Secondary | normalization rate of CRP at the 8th week | 8th-week | normalization rate of C reactive protein (CRP) |
| Secondary | life quality score at the 8th week | 8th-week | Inflammatory bowel disease questionnaire (IBDQ), the total score is 32-224, with higher scores indicating better quality of life for patients. |
| Secondary | Clinical remission rate at the 54th-week | 54th-week | clincial remisson is defined as a total Mayo score ≤2, with no individual subscore \>1 and a rectal bleeding subscore of 0. |
| Secondary | Clinical response rate at 54th week | 54th week | Clinical response is defined as a decrease in total Mayo score by ≥3 points and ≥30% from baseline, with a decrease in rectal bleeding subscore by ≥1 point or an absolute rectal bleeding subscore of 0 or 1. |
| Secondary | endoscopic remission rate at 54th-week | 54th-week | endoscopic subscale (ESS) =0, which defined as endoscopic remission |
| Secondary | Endoscopic response rate at 54th-week | 54th-week | Endoscopic response is defined as a decrease in the Mayo endoscopic subscore by ≥1 point from baseline |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42173298 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06095596
GET https://conductscience.org/api/trials/v1/NCT06095596/registered